DrugPatentWatch Database Preview

Lesinurad - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for lesinurad and what is the scope of lesinurad freedom to operate?

Lesinurad is the generic ingredient in one branded drug marketed by Ironwood Pharms Inc and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lesinurad has one hundred and seventy-five patent family members in thirty-eight countries.

Two suppliers are listed for this compound.

Summary for lesinurad

International Patents:	175
US Patents:	7
Tradenames:	1
Applicants:	1
NDAs:	1
Suppliers / Packagers:	2
Bulk Api Vendors:	42
Clinical Trials:	19
Patent Applications:	76
Drug Prices:	see low prices
DailyMed Link:	lesinurad at DailyMed

Pharmacology for lesinurad

Drug Class	Urate Transporter 1 Inhibitor
Mechanism of Action	Urate Transporter 1 Inhibitors Cytochrome P450 3A Inducers

Synonyms for lesinurad

(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid

{[5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-1,2,4-TRIAZOL-3-YL]SULFANYL}ACETIC ACID

{[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid

09ERP08I3W

2-((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)acetic acid

2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid

2-(5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid

2-[[5-Bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]-acetic acid

2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acid

2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]thio]acetic acid

2-{[5-broMo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid

3777AH

878672-00-5

Acetic acid, 2-((5-bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl)thio)-

Acetic acid,[[5-bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]-

ACN-050764

AK323774

AKOS027327368

C17H14BrN3O2S

CHEBI:90929

CHEMBL2105720

CS-1389

D09921

D0C3SW

DB11560

EX-A1289

FGQFOYHRJSUHMR-UHFFFAOYSA-N

GTPL7673

HE067018

HY-15258

KB-78121

KS-00000LAE

Lesinurad (RDEA-594)

Lesinurad (RDEA594 pound(c)

Lesinurad (RDEA594)

Lesinurad (USAN)

Lesinurad [USAN:INN]

Lesinurad, >=98% (HPLC)

MFCD22572730

MolPort-039-138-666

RDEA 594

RDEA-594

RDEA594

s4640

SC-94287

SCHEMBL842962

UNII-09ERP08I3W

W-5949

ZINC84757007

Zurampic

Zurampic (TN)

US Patents and Regulatory Information for lesinurad

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ironwood Pharms Inc	ZURAMPIC	lesinurad	TABLET;ORAL	207988-001	Dec 22, 2015		RX	Yes	Yes
Ironwood Pharms Inc	ZURAMPIC	lesinurad	TABLET;ORAL	207988-001	Dec 22, 2015		RX	Yes	Yes
Ironwood Pharms Inc	ZURAMPIC	lesinurad	TABLET;ORAL	207988-001	Dec 22, 2015		RX	Yes	Yes
Ironwood Pharms Inc	ZURAMPIC	lesinurad	TABLET;ORAL	207988-001	Dec 22, 2015		RX	Yes	Yes				Y

Non-Orange Book US Patents for lesinurad

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,242,154	Compounds, compositions and methods of using same for modulating uric acid levels
8,344,012	Compounds, compositions and methods of using same for modulating uric acid levels
8,633,232	Compounds, compositions and methods of using same for modulating uric acid levels
7,947,721	S-triazolyl .alpha.-mercaptoacetanilides as inhibitors of HIV reverse transcriptase

International Patents for lesinurad

Country	Document Number	Estimated Expiration
Taiwan	I452037
Portugal	2217577
Israel	181523
Eurasian Patent Organization	201370150

Supplementary Protection Certificates for lesinurad

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
/2016	Austria		PRODUCT NAME: LESINURAD ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1080 (MITTEILUNG) 20160222
0825	Netherlands		PRODUCT NAME: LESINURAD; REGISTRATION NO/DATE: EU/1/15/1080 20160222
2016000060	Germany		PRODUCT NAME: LESINURAD ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1080 20160218
0160027 00203	Estonia		PRODUCT NAME: LESINURAAD;REG NO/DATE: EU/1/15/1080 22.02.2016